Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies, where legally permitted, to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify leading and emerging global companies for its portfolio that are innovating in the sector and are supported by science. Learn more: https://originpsychedelics.com/
Dimensions Health is focused on developing psychedelic inspired retreats, starting with its flagship property in Maple Lake, Ontario. Origin invested in Dimension’s initial seed round and provided guidance on its real estate financing initiatives. Dimensions is currently raising $12.5M in its Series A round, representing a 3x unrealized return on Origin’s initial investment.
MicroDose is a psychedelic industry-focused media company that distributes and creates compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. Origin provided seed capital to MicroDose.
TripSitteris a oral ketamine treatment program delivered online by licensed physicians. TripSitter’sprogram provides deep and sustained relief for both mild and severe depression, anxiety, and trauma-related mental health conditions.
Xpira is focused on the development, production, and marketing of psychedelic-based products, as legally permitted, with clinically proven efficacy. Xpira’steam was formed by leaders in the Canadian and Dutch pharmaceutical industries with proven track records and a deep understanding of the pharmaceutical development pathways to bring drug candidates to market.
Ocean is an early-stage drug discovery company that is focused on the design of novel psychedelic therapeutics (as compared to using traditional psychedelics, such as psilocybin, LSD, ketamine, etc.). Ocean’s mission is to develop novel CNS drugs, as legally permitted, that may have desirable therapeutic applications, while minimizing possible negative side effects that are otherwise associated with traditional psychedelics.